Today: 19 January 2026
Subscribe
Browse Category

Pharma News News 16 December 2025 - 26 December 2025

Zai Lab Limited Stock (NASDAQ: ZLAB) Today: Pre‑Market Watchlist After China’s COBENFY Approval, NRDL Renewals, and Fresh Pipeline Catalysts

Zai Lab Limited Stock (NASDAQ: ZLAB) Today: Pre‑Market Watchlist After China’s COBENFY Approval, NRDL Renewals, and Fresh Pipeline Catalysts

New York — Friday, December 26, 2025, 9:08 a.m. ET. U.S. equities are not yet in the regular session as of this writing; the Nasdaq opens at 9:30 a.m. ET. Barron’s That timing matters today because Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is entering the session with multiple company-specific catalysts on the board—most notably China’s approval of COBENFY for…
26 December 2025
···
Panacea Biotec Share Price Surges on UNICEF Vaccine Contract Upgrade: News, Forecasts and Stock Analysis for 26 December 2025

Panacea Biotec Share Price Surges on UNICEF Vaccine Contract Upgrade: News, Forecasts and Stock Analysis for 26 December 2025

Panacea Biotec Limited (NSE: PANACEABIO, BSE: 531349) became one of India’s standout movers on Friday, December 26, 2025, after the company disclosed a meaningful upgrade to its UNICEF vaccine supply award—an update that immediately lit up the stock tape even as the broader market drifted in thin year-end trade. Business Standard By midday, Panacea Biotec’s share price was sharply higher…
26 December 2025
····
AbbVie (ABBV) Stock News Today, Dec. 23, 2025: Beyond Botox Pipeline Push, Analyst Targets, and What to Watch Next

AbbVie (ABBV) Stock News Today, Dec. 23, 2025: Beyond Botox Pipeline Push, Analyst Targets, and What to Watch Next

AbbVie Inc. (NYSE: ABBV) stock traded mostly steady to slightly higher on Tuesday, Dec. 23, 2025, as investors balanced a holiday-shortened trading week with a fresh burst of company-specific pipeline headlines and ongoing debate about U.S. drug-pricing policy. As of Tuesday afternoon, ABBV changed hands around $228.62, up about 0.31% on the day, after trading in a $227.88–$230.77 range. What…
23 December 2025
····
Insmed (INSM) Stock News Today: Nasdaq‑100 Addition, Brensocatib Setback, and Updated Analyst Forecasts (Dec. 22, 2025)

Insmed (INSM) Stock News Today: Nasdaq‑100 Addition, Brensocatib Setback, and Updated Analyst Forecasts (Dec. 22, 2025)

Insmed Incorporated (NASDAQ: INSM) is ending 2025 with two headlines pulling the stock in opposite directions: fresh visibility from joining the Nasdaq‑100 Index and fresh volatility after a clinical disappointment for a key expansion effort. As of Monday, December 22, 2025 (17:56 UTC), INSM traded at $177.86, up about $3.02 (~1.7%) on the day, after swinging sharply in recent sessions.…
22 December 2025
···
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $4.8B Cash Buyout at $14.50 Resets the Outlook (Dec. 20, 2025)

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $4.8B Cash Buyout at $14.50 Resets the Outlook (Dec. 20, 2025)

December 20, 2025 — Amicus Therapeutics, Inc. (NASDAQ: FOLD) has abruptly shifted from a “rare-disease growth story” to a merger-arbitrage stock after BioMarin Pharmaceutical announced a definitive, all-cash acquisition valued at roughly $4.8 billion. The headline number for shareholders: $14.50 per share in cash, a premium of about 33% to Amicus’ prior close. Reuters On December 19, FOLD shares surged…
20 December 2025
····
GSK plc Stock News and Forecast (Dec. 20, 2025): TrumpRx Pricing Deal, Exdensur FDA Approval, Buybacks, and Analyst Targets

GSK plc Stock News and Forecast (Dec. 20, 2025): TrumpRx Pricing Deal, Exdensur FDA Approval, Buybacks, and Analyst Targets

GSK plc (LSE: GSK; NYSE: GSK) heads into the weekend with a rare “everything-bagel” mix of catalysts: a new U.S. drug-pricing agreement tied to tariff relief, a fresh FDA approval that could reshape severe-asthma dosing schedules, expanding vaccine indications in Europe, and a steady drumbeat of buybacks. For investors tracking GSK stock, the headline isn’t just one event—it’s the way…
20 December 2025
····
Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts

Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts

December 18, 2025 — Insmed Incorporated (NASDAQ: INSM) shares dropped sharply Thursday after the company disclosed a Phase 2b setback for brensocatib in a chronic sinus condition and said it is discontinuing development in that indication, even as it simultaneously added a new Phase 2–ready antibody to its pipeline. SEC Insmed stock was trading around $166.75 in the afternoon snapshot…
18 December 2025
····
Johnson & Johnson Stock After Hours (Dec. 17, 2025): JNJ Closes Higher on FDA News—What to Know Before the Market Opens Thursday

Johnson & Johnson Stock After Hours (Dec. 17, 2025): JNJ Closes Higher on FDA News—What to Know Before the Market Opens Thursday

Johnson & Johnson (NYSE: JNJ) ended Wednesday’s session modestly higher—an eye-catching show of relative strength on a down day for major U.S. indexes—while investors digested a fresh FDA approval tied to the company’s lung cancer franchise and looked ahead to a potentially market-moving inflation print before Thursday’s open. After the closing bell on Dec. 17, 2025, JNJ shares finished at…
18 December 2025
····
Eli Lilly Stock News Today (Dec. 17, 2025): LLY Holds Near Record Highs as Analysts Lift Targets and Obesity Pipeline Momentum Builds

Eli Lilly Stock News Today (Dec. 17, 2025): LLY Holds Near Record Highs as Analysts Lift Targets and Obesity Pipeline Momentum Builds

Eli Lilly and Company (NYSE: LLY) stock traded in the mid-$1,050s in U.S. session Wednesday, December 17, 2025, hovering near recent highs as investors weighed fresh analyst commentary and new partnership headlines against an already-strong run for the pharma giant. In early trading, LLY was modestly higher, with the session range spanning roughly $1,051 to $1,064. The near-term story for…
17 December 2025
···
GSK Stock News Today (Dec. 17, 2025): FDA Approves Twice‑Yearly Asthma Drug Exdensur as Analysts Reassess GSK plc’s 2026 Outlook

GSK Stock News Today (Dec. 17, 2025): FDA Approves Twice‑Yearly Asthma Drug Exdensur as Analysts Reassess GSK plc’s 2026 Outlook

Updated: 17 December 2025 GSK plc stock (LSE: GSK; NYSE: GSK) is in focus on Dec. 17 after a major U.S. regulatory win: the FDA approved Exdensur (depemokimab‑ulaa) for severe asthma—giving GSK a new, ultra‑long‑acting biologic that’s dosed just twice a year. The approval lands as the company approaches a leadership handover on Jan. 1, 2026, and as investors weigh…
17 December 2025
···
Pfizer Stock After Hours Today (Dec. 16, 2025): PFE Drops on 2026 Outlook—What to Know Before the Market Opens Dec. 17

Pfizer Stock After Hours Today (Dec. 16, 2025): PFE Drops on 2026 Outlook—What to Know Before the Market Opens Dec. 17

Pfizer Inc. (NYSE: PFE) finished Tuesday’s session sharply lower after investors digested the company’s newly issued full‑year 2026 financial guidance—and the market’s message was clear: Wall Street wants more certainty on when Pfizer’s post‑COVID growth engine fully re-ignites. Pfizer stock price after the bell: where PFE stands tonight Pfizer shares closed at $25.53, down 3.41% on the day, then edged…
16 December 2025
····
Bristol-Myers Squibb (BMY) Stock News Today: BofA Upgrade, Dividend Momentum and 2026 Pipeline Catalysts in Focus (Dec. 16, 2025)

Bristol-Myers Squibb (BMY) Stock News Today: BofA Upgrade, Dividend Momentum and 2026 Pipeline Catalysts in Focus (Dec. 16, 2025)

Bristol-Myers Squibb Company (NYSE: BMY) is back in the spotlight on Tuesday, December 16, 2025, as investors weigh a fresh Bank of America upgrade, a renewed value debate around the stock’s multiple, and a growing list of 2026 pipeline catalysts that could shape the post–patent-cliff narrative. As of 2:00 p.m. (quotes delayed), BMY shares were $53.66, down 1.15% on the…
16 December 2025
····
1 2 3 4 5 6 … 10

Stock Market Today

  • XBM Stock Analysis and AI-Generated Trading Signals for iShares Metals ETF
    January 19, 2026, 12:53 PM EST. On January 19, 2026, the iShares S&P/TSX Global Base Metals Index ETF (XBM:CA) received mixed AI-generated ratings. The near-term outlook is rated Strong, signaling potential short-term gains. However, both mid-term and long-term ratings are Weak, indicating cautious sentiment ahead. The suggested trading plan advises a buy near $20.96 with a stop loss at $20.86 to limit downside risk. No short-selling recommendations are presently offered. These signals stem from AI analysis incorporating market data up to the time of update, providing traders with timely insights on XBM's performance prospects.
Go toTop